A randomised controlled trial of effectiveness and safety of Niclosamide as add on therapy to the standard of care measures in COVID-19 management.
COVID-19
Niclosamaide
SARS-COV2
Standard of care
Journal
Annals of medicine and surgery (2012)
ISSN: 2049-0801
Titre abrégé: Ann Med Surg (Lond)
Pays: England
ID NLM: 101616869
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
08
08
2021
revised:
23
08
2021
accepted:
02
09
2021
entrez:
13
9
2021
pubmed:
14
9
2021
medline:
14
9
2021
Statut:
ppublish
Résumé
COVID-19 pandemic has ignited the urge for repurposing old drugs as candidate antiviral medicines to treat novel challenges of viral infections. Niclosamide (NCS) is an anti-parasitic drug of known antiviral potential. Therefore, this study attempts to investigate the antiviral effect and safety of NCS on SARS-CoV-2 caused COVID-19 patients. Randomized controlled open label clinical trial encompassed 75 COVID-19 patients treated with standard of care plus NCS were included as experimental group and 75 COVID-19 patients treated with only standard of care therapy as control group. Survival rate, time to recovery, and side effects were the main endpoints for the assessment of the therapeutic effect and safety of NCS. No significant difference between the two study groups in the incidence of death Vs recovery within 30 days of follow up(p = 1).Median survival time to cure in the NCS addon group was significantly less than controls (5 Vs 7days, Log rank p = 0.005).All the recoveries took place within 20 days in the NCS add on group, which is 10 days shorter than that in the controls (30 days), NCS add on treatment increased the risk of cure by 60% per day compared to control group (adjusted HR = 1.6,p = 0,007) after adjusting for the count of comorbidities. Additionally, two or more comorbidities reduced the risk of cure to 33% (p < 0.001).Male gender increased the risk of cure by 42% (p = 0.046). Older age group decreased the risk of recovery per day to 0.58 and 0.53 for 50-59 and 60+ years of age. Hyypertension (HT) and diabetes mellitus (DM) significantly reduced the risk of being cured per day to 0.56 (p = 0.003)and 0.65 (p = 0.039) respectively. No significant signals of safety in NCS add on therapy compared to control group. adding NCS to the standards of care measures increased the risk of the cure and had shorter time to stay in the hospital compared with controls., male gender increased the risk of cure, while older patients>40 years, HT, and DM decreased the risk of cure. Also, NCS add on therapy was relatively safe; hence, NCS is of clinical benefit for freeing hospital beds for more patients in pandemic crisis.
Sections du résumé
BACKGROUND
BACKGROUND
COVID-19 pandemic has ignited the urge for repurposing old drugs as candidate antiviral medicines to treat novel challenges of viral infections. Niclosamide (NCS) is an anti-parasitic drug of known antiviral potential. Therefore, this study attempts to investigate the antiviral effect and safety of NCS on SARS-CoV-2 caused COVID-19 patients.
METHODS
METHODS
Randomized controlled open label clinical trial encompassed 75 COVID-19 patients treated with standard of care plus NCS were included as experimental group and 75 COVID-19 patients treated with only standard of care therapy as control group. Survival rate, time to recovery, and side effects were the main endpoints for the assessment of the therapeutic effect and safety of NCS.
RESULTS
RESULTS
No significant difference between the two study groups in the incidence of death Vs recovery within 30 days of follow up(p = 1).Median survival time to cure in the NCS addon group was significantly less than controls (5 Vs 7days, Log rank p = 0.005).All the recoveries took place within 20 days in the NCS add on group, which is 10 days shorter than that in the controls (30 days), NCS add on treatment increased the risk of cure by 60% per day compared to control group (adjusted HR = 1.6,p = 0,007) after adjusting for the count of comorbidities. Additionally, two or more comorbidities reduced the risk of cure to 33% (p < 0.001).Male gender increased the risk of cure by 42% (p = 0.046). Older age group decreased the risk of recovery per day to 0.58 and 0.53 for 50-59 and 60+ years of age. Hyypertension (HT) and diabetes mellitus (DM) significantly reduced the risk of being cured per day to 0.56 (p = 0.003)and 0.65 (p = 0.039) respectively. No significant signals of safety in NCS add on therapy compared to control group.
CONCLUSION
CONCLUSIONS
adding NCS to the standards of care measures increased the risk of the cure and had shorter time to stay in the hospital compared with controls., male gender increased the risk of cure, while older patients>40 years, HT, and DM decreased the risk of cure. Also, NCS add on therapy was relatively safe; hence, NCS is of clinical benefit for freeing hospital beds for more patients in pandemic crisis.
Identifiants
pubmed: 34512959
doi: 10.1016/j.amsu.2021.102779
pii: S2049-0801(21)00729-9
pmc: PMC8416702
doi:
Types de publication
Journal Article
Langues
eng
Pagination
102779Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
None.
Références
Emerg Microbes Infect. 2020 Dec;9(1):727-732
pubmed: 32196410
Chin J Cancer. 2012 Apr;31(4):178-84
pubmed: 22237038
Virol J. 2010 Oct 11;7:264
pubmed: 20937137
Front Pharmacol. 2019 Feb 14;10:51
pubmed: 30837866
Lancet. 2016 Feb 20;387(10020):719-21
pubmed: 26876373
JCI Insight. 2019 Aug 8;4(15):
pubmed: 31391337
Microbes Infect. 2020 Mar;22(2):74-79
pubmed: 32017984
Nat Commun. 2019 Dec 18;10(1):5770
pubmed: 31852899
Pharmacol Ther. 1982;19(2):245-95
pubmed: 6763710
PLoS Pathog. 2012;8(10):e1002976
pubmed: 23133371
Trends Pharmacol Sci. 2014 Feb;35(2):86-102
pubmed: 24439476
J Med Virol. 2020 May;92(5):479-490
pubmed: 32052466
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
ACS Infect Dis. 2020 May 8;6(5):909-915
pubmed: 32125140
PLoS One. 2015 Apr 21;10(4):e0124595
pubmed: 25897961
Antiviral Res. 2016 Nov;135:81-90
pubmed: 27742486
Viruses. 2021 Apr 09;13(4):
pubmed: 33918958
Antimicrob Agents Chemother. 2004 Jul;48(7):2693-6
pubmed: 15215127
Med Hypotheses. 2019 Aug;129:109241
pubmed: 31371076